You are here

Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Loyola University Medical Center, Foster G. McGraw Hospital and Satellites
Maywood, Illinois, 60153 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
B-Cell Lymphoma
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- CD20/CD22-positive diffuse large B-cell NHL that has relapsed after 1 or 2 prior
therapies; one prior therapy must include anthracyclines and one must include
rituximab in combination with chemotherapy

- Relapsed/disease progression within 12 months after start of prior therapy and/or
secondary International Prognostic Index (sIPI) score greater than 1

- Eligible for autologous stem cell transplant (aSCT)

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Prior allogeneic hematopoietic stem cell transplant

- Within 6 months prior to test article: autologous transplant, treatment with anti-CD22
antibodies, radio-immunotherapy

- Veno-occlusive disease or sinusoidal obstruction syndrome, chronic liver disease,
systemic vasculitides, current or chronic hepatitis B or C infection

NCT00867087
Pfizer
Completed
Study Evaluating Inotuzumab Ozogamicin (CMC-544) Plus Rituximab In Diffuse Large B-Cell Non-Hodgkin's Lymphoma

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now